Find research datasets worth reusing

opencc-by-4.0Jan 2023View details →

Ki-67 and Bcl-2 data by flow cytometry in non-malignant bone marrow aspirates and aspirates from patients with myeloid malignancies.

This Data in Brief article displays a flow cytometric assay that was used for the acquisition and analyses of proliferation and anti-apoptosis in hematopoietic cells. This dataset includes analysis of the Ki-67 positive fraction (Ki-67 proliferation index) and Bcl-2 positive fraction (Bcl-2 anti-apoptotic index) of the different myeloid bone marrow (BM) cell population in non-malignant BM, and the BM disorders myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The present dataset comprises 1) the percentage of the CD34 positive blast cells, erythroid cells, myeloid cells and monocytic cells, and 2) the determined Ki-67 positive fraction and Bcl-2 positive fraction of these cell populations in tabular form. This allows the comparison and reproduction of the data when these analyses are repeated in a different setting. As gating the Ki-67 positive and Bcl-2 positive cells is a critical step in this assay, different gating approaches were compared to determine the most sensitive and specific approach. BM cells from aspirates of 50 non-malignant, 25 MDS and 50 AML cases were stained with 7 different antibody panels and subjected to flow cytometry for determination of the Ki-67 positive cells and Bcl-2 positive cells of the different myeloid cell populations. The Ki-67 or Bcl-2 positive cells were then divided by the total number of cells of the respective cell population to generate the Ki-67 positive fraction (Ki-67 proliferation index) or the Bcl-2 positive fraction (Bcl-2 anti-apoptotic index). The presented data may facilitate the establishment and standardization of flow cytometric analyses of the Ki-67 proliferation index and Bcl-2 anti-apoptotic index of the different myeloid cell populations in non-malignant BM as well as MDS and AML patients in other laboratories. Directions for proper gating of the Ki-67 positive and Bcl-2 positive fraction are crucial for achieving standardization among different laboratories. In addition, the data and the presented assay allows application of Ki-67 and Bcl-2 in a research and clinical setting and this approach can serve as the basis for optimization of the gating strategy and subsequent investigation of other cell biological processes besides proliferation and anti-apoptosis. These data can also promote future research about the role of these parameters in diagnosis of myeloid malignancies, prognosis of myeloid malignancies and therapeutic resistance against anti-cancer therapies in these malignancies. As specific populations based on cell biological characteristics were identified, these data can be useful for evaluating gating algorithms in flow cytometry in general by confirming the outcome (e.g. MDS or AML diagnosis) with the respective proliferation and anti-apoptotic profile of these malignancies. The Ki-67 proliferation index and Bcl-2 anti-apoptotic index may potentially be used for classification of MDS and AML based on supervised machine learning algorithms, while unsupervised machine learning can be deployed at the level of single cells to potentially distinguish non-malignant from malignant cells to identify minimal residual disease. Therefore, the present dataset may be of interest for internist-hematologists, immunologists with affinity for hemato-oncology, clinical chemists with sub-specialization of hematology and researchers in the field of hemato-oncology.

opencc-by-4.0Dec 2022View details →

B-cell receptor data from intratumoural B cells in melanoma patients

This record contains data used in the Crescioli et al. analysis of B-cell response in melanoma, specifically analysis concerning high-throughput BCR repertoire. Files: "Visium_all_Aug22_comboDatBoth.txt": IMGT/HighV-Quest output of the high-throughput intratumoural BCR repertoire from n=5 melanoma tumours. In tab-separated text file format. "HV_EB_COV_MEL_comb_Oct22.RDS": A R data object (readable into R with "readRDS(...)") containing combined data from the melanoma (MEL) data with analogous high-throughput BCR repertoire data from healthy volunteers (HV), Ebola convalescent patients (EB) and hospitalised COVID-19 patients (COV). HV, EB and COV data are taken from <a href="https://dx.doi.org/10.5281/zenodo.5146019">https://dx.doi.org/10.5281/zenodo.5146019</a>. Here the sequences are filtered to contain only unique combinations of isotype and IMGT-numbered V-domain DNA sequence (to remove redundancies due to e.g. capturing BCR transcripts from plasma cells). "BM_Master_Light_Useasreftrue_140325_withPepStats_8.csv". IMGT/HighV-Quest output of the Bone Marrow light chain repertoire data. <a href="https://doi.org/10.3389/fimmu.2016.00388">Published in Townsend et al. Front Immunol 7:388 (2016)</a>. Used here for the comparison of gene conversion frequencies against the melanoma light chain repertoire. "BM_Master_Light_Useasreftrue_140325_withPepStats_8_Vgapped.fasta". The IMGT-gapped V-gene sequence from the Townsend et al. (see above) Bone Marrow light chain repertoire data. This is the raw input to BrepConvert. Provided here for this dataset; same sequences for the melanoma/healthy data are already in the RDS object ("HV_EB_COV_MEL_comb_Oct22.RDS"). "2_IMGT-gapped-nt-sequences_visa.txt", "2_IMGT-gapped-nt-sequences_visb.txt": Raw output of IMGT/HighV-Quest containing IMGT-gapped nucleotide sequences. These files were parsed to extract the IMGT-gapped V-gene sequence for BrepConvert analysis. "BrepConvert.zip": BrepConvert gene conversion analysis results for Healthy and Melanoma repertoires. See code in <a href="https://github.com/josef0731/melanoma-ig">https://github.com/josef0731/melanoma-ig</a> for ways to use these input files for reproducing the analyses.

Raw Data for the article: Brain magnetic resonance imaging radiomics features associated with hepatic encephalopathy in adult cirrhotic patients

Purpose: Hepatic encephalopathy (HE) is a potential complication of cirrhosis. Magnetic resonance imaging (MRI) may demonstrate hyperintense T1 signal in the globi pallidi. The purpose of this study was to evaluate the performance of MRI-based radiomic features for diagnosing and grading chronic HE in adult patients affected by cirrhosis. Methods: Adult patients with and without cirrhosis underwent brain MRI with identical imaging protocol on a 3T scanner. Patients without history of chronic liver disease were the control population. HE grading was based on underlying liver disease, severity of clinical manifestation, and number of encephalopathic episodes. Texture analysis was performed on axial T1-weighted images on bilateral lentiform nuclei at the level of the foramina of Monro. Diagnostic performance of texture analysis for the diagnosis and grading of HE was assessed by calculating the area under the receiver operating characteristics (AUROC) with 95% confidence interval (CI). Results: The final study population consisted of 124 patients, 70 cirrhotic patients, and 54 non-cirrhotic controls. Thirty-eight patients had history of HE with 22 having an HE grade > 1. The radiomic features predicted the presence of HE with an AUROC of 0.82 (95% CI: 0.73, 0.90; P < .0001; 82% sensitivity, 66% specificity). Radiomic features predicted grade 1 HE (AUROC 0.75; 95% CI: 0.61, 0.89; P < .0001; 94% sensitivity, 60% specificity) and grade ≥ 2 HE (AUROC 0.82; 95% CI: 0.71, 0.93; P < .0001, 95% sensitivity, 57% specificity). Conclusion: In cirrhotic patients, MR radiomic is effective in predicting the presence of chronic HE and in grading its severity.

Raw Data for the article: Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model

Background and aims: Implantation of a transjugular intrahepatic portosystemic shunt (TIPS) improves survival in patients with cirrhosis with refractory ascites and portal hypertensive bleeding. However, the indication for TIPS in older adult patients (greater than or equal to 70 years) is debated, and a specific prediction model developed in this particular setting is lacking. The aim of this study was to develop and validate a multivariable model for an accurate prediction of mortality in older adults. Approach and results: We prospectively enrolled 411 consecutive patients observed at four referral centers with de novo TIPS implantation for refractory ascites or secondary prophylaxis of variceal bleeding (derivation cohort) and an external cohort of 415 patients with similar indications for TIPS (validation cohort). Older adult patients in the two cohorts were 99 and 76, respectively. A cause-specific Cox competing risks model was used to predict liver-related mortality, with orthotopic liver transplant and death for extrahepatic causes as competing events. Age, alcoholic etiology, creatinine levels, and international normalized ratio in the overall cohort, and creatinine and sodium levels in older adults were independent risk factors for liver-related death by multivariable analysis. Conclusions: After TIPS implantation, mortality is increased by aging, but TIPS placement should not be precluded in patients older than 70 years. In older adults, creatinine and sodium levels are useful predictors for decision making. Further efforts to update the prediction model with larger sample size are warranted.

Raw Data for the article: COVID-19 safety measures at the Radiology Unit of a Transplant Institute: the non-COVID-19 patient's confidence with safety procedures

Purpose: To support the wellbeing of both patients and their families, our aim was to investigate the satisfaction of non-COVID in- and out-patients regarding safety measures implemented at our radiology unit of a transplant institute against COVID infection. Materials and methods: Over a five-month period, adult patients' feedback was obtained by a questionnaire on the fear of contracting COVID-19 during a radiology examination, the perceived delay in treatment, and the following safety measures implemented: modified schedules to limit the number of patients in the waiting area and to maximize social distancing; assistance by staff when visitors were not admitted; cleaning and disinfection of machines; mask wearing and hand hygiene of staff; and staff advice on hand hygiene and infection control precautions. Results: Over a five-month period, our preliminary results (387 patients) showed general patient satisfaction (99.1%) with safety measures applied at our radiology unit. Patients were satisfied with distancing and assistance by staff (100%), cleaning and disinfection (91%), mask wearing and hand hygiene of the staff (97%), and staff advice (94%). There was some criticism of the perceived delay in treatment (7.3%) and in the scheduling of the waiting list (5.4%), with 5.4% fearing contracting the virus. Patients' awareness of safety measures and confidence in the hospital preparedness policy was perceived by all interviewers, and 100% appreciated being questioned. Conclusion: The feedback given by the non-COVID patient helps to measure the quality in health care, to improve the quality service, and to protect and satisfy more vulnerable patients, also during the COVID-19 pandemic.

Raw Data for the article: How important is the role of iterative liver direct surgery in patients with hepatocellular carcinoma for a transplant center located in an area with a low rate of deceased donation?

Introduction: Hepatocellular carcinoma (HCC) accounts for nearly 90% of primary liver cancers, with estimates of over 1 million people affected by 2025. We aimed to explore the impacting role of an iterative surgical treatment approach in a cohort of HCC patients within the Milan criteria, associated with clinical risk factors for tumor recurrence (RHCC) after liver transplant (LT) and loco-regional therapies (LRT), as well as liver resection (LR) and/or microwave thermal ablation (MWTA). Methods: We retrospectively analyzed our experience performed during an 8-year period between January 2013 and December 2021 in patients treated for HCC, focusing on describing the impact on preoperative end-stage liver disease severity, oncologic staging, tumor characteristics, and surgical treatments. The Cox model was used to evaluate variables that could predict relapse risks. Relapse risk curves were calculated according to the Kaplan-Meier method, and the log-rank test was used to compare them. Results: There were 557 HCC patients treated with a first-line approach of LR and/or LRTs (n = 335) or LT (n = 222). The median age at initial transplantation was 59 versus 68 for those whose first surgical approach was LR and/or LRT. In univariate analysis with the Cox model, nodule size was the single predictor of recurrence of HCC in the posttreatment setting (HR: 1.61, 95% CI: 1.05-2.47, p = 0.030). For the LRT group, we have enlightened the following clinical characteristics as significantly associated with RHCC: hepatitis B virus infection (which has a protective role with HR: 0.34, 95% CI: 0.13-0.94, p = 0.038), number of HCC nodules (HR: 1.54, 95% CI: 1.22-1.94, p < 0.001), size of the largest nodule (HR: 1.06, 95% CI: 1.01-1.12, p = 0.023), serum bilirubin (HR: 1.57, 95% CI: 1.03-2.40, p = 0.038), and international normalized ratio (HR: 16.40, 95% CI: 2.30-118.0, p = 0.006). Among the overall 111 patients with RHCC in the LRT group, 33 were iteratively treated with further curative treatment (12 were treated with LR, two with MWTA, three with a combined LR-MWTA treatment, and 16 underwent LT). Only one of 18 recurrent patients previously treated with LT underwent LR. For these RHCC patients, multivariable analysis showed the protective roles of LT for primary RHCC after IDLS (HR: 0.06, 95% CI: 0.01-0.36, p = 0.002), of the time relapsed between the first and second IDLS treatments (HR: 0.97, 95% CI: 0.94-0.99, p = 0.044), and the impact of previous minimally invasive treatment (HR: 0.28, 95% CI: 0.08-1.00, p = 0.051). Conclusion: The coexistence of RHCC with underlying cirrhosis increases the complexity of assessing the net health benefit of ILDS before LT. Minimally invasive surgical therapies and time to HCC relapse should be considered an outcome in randomized clinical trials because they have a relevant impact on tumor-free survival.

Supporting data and analysis for," A spatially anchored transcriptomic atlas of the human kidney papilla identifies significant immune injury in patients with stone disease", main figures PART 1

This deposit contains the supporting records of images and image analysis  presented in, " A spatially anchored transcriptomic atlas of the human kidney papilla identifies significant immune injury in patients with stone disease".  doi: https://doi.org/10.1101/2022.06.22.497218 Associated Zenodo repositories: <table> <thead> <tr> <th scope="col">Description</th> <th scope="col">DOI</th> </tr> </thead> <tbody> <tr> <td>Main figures PART 1, Figure 1,2,3,5</td> <td>10.5281/zenodo.7653239</td> </tr> <tr> <td>Main figures PART 2, Figure 6</td> <td>10.5281/zenodo.7900973</td> </tr> <tr> <td>Supplemental 3DTC figures: S1, S4, S5, S7, S8, S9</td> <td>10.5281/zenodo.7894632</td> </tr> </tbody> </table> Contents:1) a collection of .zip files contains the 3D tissue cytometry files for tissue analyzed in the manuscript doi: https://doi.org/10.1101/2022.06.22.497218.  This collection includes the individual analyses for figures 2, 3 and 5.  Figure 6 analyses are included in a compansion repository: 10.5281/zenodo.7900973.  Contents of zip files by figure contain at a minimum the .obx and a .tif file which includes the segmented objects and associated measurements for use by VTEA (https://vtea.wiki/).  Additional files may include gate files (.vtg) or max projections (.tif). 2) a collection of zip files containing the RNAScope image files shown in: Figure 1 P,Q. The supplemental figure data for RNAScope. Figures S1,S4 and S5 are found in: 10.5281/zenodo.7894633. Please address any concerns or questions to the authors listed in the deposit or manuscript, doi: https://doi.org/10.1101/2022.06.22.497218

opencc-by-4.0May 2023View details →

Supporting data and analysis for," A spatially anchored transcriptomic atlas of the human kidney papilla identifies significant immune injury in patients with stone disease", Supplemental 3DTC figures

This deposit contains the supporting records of analysis for 3D cytometry presented in, " A spatially anchored transcriptomic atlas of the human kidney papilla identifies significant immune injury in patients with stone disease".  doi: https://doi.org/10.1101/2022.06.22.497218 found in supplemental figures. Contents: 1) a collection of .zip files contains the 3D tissue cytometry files for tissue analyzed in the manuscript doi: https://doi.org/10.1101/2022.06.22.497218.  This collection includes the individual analyses by figures in the supplemental figure data for 3D tissue cytometry.  The main figure data is found at: 10.5281/zenodo.7653239 and 10.5281/zenodo.7900973. 2) a collection of zip files containing the RNAScope image files shown in:  Figures S1,S4 and S5. The main RNAScope figure data is found at: 10.5281/zenodo.7653239 Please address any concerns or questions to the authors listed in the deposit or manuscript, doi: https://doi.org/10.1101/2022.06.22.497218

opencc-by-4.0May 2023View details →

Supporting data and analysis for," A spatially anchored transcriptomic atlas of the human kidney papilla identifies significant immune injury in patients with stone disease", main figures PART 2

This deposit contains the supporting records of analysis for 3D cytometry presented in, " A spatially anchored transcriptomic atlas of the human kidney papilla identifies significant immune injury in patients with stone disease".  doi: https://doi.org/10.1101/2022.06.22.497218 Contents: 1) a collection of .zip files contains the 3D tissue cytometry files for tissue analyzed in the manuscript doi: https://doi.org/10.1101/2022.06.22.497218.  This collection includes the individual analyses for figure 6 analyses. Contents of zip files by figure contain at a minimum the .obx and a .tif file which includes the segmented objects and associated measurements for use by VTEA (https://vtea.wiki/).  Additional files may include gate files (.vtg) or max projections (.tif).   Please address any concerns or questions to the authors listed in the deposit or manuscript, doi: https://doi.org/10.1101/2022.06.22.497218

Ki-67 and Bcl-2 data by flow cytometry in non-malignant bone marrow aspirates and patients with myeloid malignancies

This Data in Brief article displays a flow cytometric assay that was used for the acquisition and analyses of proliferative and anti-apoptotic activity in hematopoietic cells. This dataset includes analyses of the Ki-67 positive fraction (Ki-67 proliferation index) and Bcl-2 positive fraction (Bcl-2 anti-apoptotic index) of the different myeloid bone marrow (BM) cell populations in non-malignant BM, and in BM disorders, i.e. myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The present dataset comprises 1) the percentage of the CD34 positive blast cells, erythroid cells, myeloid cells and monocytic cells, and 2) the determined Ki-67 positive fraction and Bcl-2 positive fraction of these cell populations in tabular form. This allows the comparison and reproduction of the data when these analyses are repeated in a different setting. Because gating the Ki-67 positive and Bcl-2 positive cells is a critical step in this assay, different gating approaches were compared to determine the most sensitive and specific approach. BM cells from aspirates of 50 non-malignant, 25 MDS and 27 AML cases were stained with 7 different antibody panels and subjected to flow cytometry for determination of the Ki-67 positive cells and Bcl-2 positive cells of the different myeloid cell populations. The Ki-67 or Bcl-2 positive cells were then divided by the total number of cells of the respective cell population to generate the Ki-67 positive fraction (Ki-67 proliferation index) or the Bcl-2 positive fraction (Bcl-2 anti-apoptotic index). The presented data may facilitate the establishment and standardization of flow cytometric analyses of the Ki-67 proliferation index and Bcl-2 anti-apoptotic index of the different myeloid cell populations in non-malignant BM as well as MDS and AML patients in other laboratories. Directions for proper gating of the Ki-67 positive and Bcl-2 positive fraction are crucial for achieving standardization among different laboratories. In addition, the data and the presented assay allows application of Ki-67 and Bcl-2 in a research and clinical setting and this approach can serve as the basis for optimization of the gating strategy and subsequent investigation of other cell biological processes besides proliferation and anti-apoptosis. These data can also promote future research into the role of these parameters in diagnosis of myeloid malignancies, prognosis of myeloid malignancies and therapeutic resistance against anti-cancer therapies in these malignancies. As specific populations were identified based on cell biological characteristics, these data can be useful for evaluating gating algorithms in flow cytometry in general by confirming the outcome (e.g. MDS or AML diagnosis) with the respective proliferation and anti-apoptotic profile of these malignancies. The Ki-67 proliferation index and Bcl-2 anti-apoptotic index may potentially be used for classification of MDS and AML based on supervised machine learning algorithms, while unsupervised machine learning can be deployed at the level of single cells to potentially distinguish non-malignant from malignant cells in the identification of minimal residual disease. Therefore, the present dataset may be of interest for internist-hematologists, immunologists with affinity for hemato-oncology, clinical chemists with sub-specialization of hematology and researchers in the field of hemato-oncology.

opencc-by-4.0Dec 2022View details →

Data for "Analysis of Wilms' tumor protein 1 specific TCR repertoire in AML patients uncovers higher diversity in patients in remission than in relapsed"

This folder holds the data for the paper "Analysis of Wilms' tumor protein 1 specific TCR repertoire in AML patients uncovers higher diversity in patients in remission than in relapsed" (in submission) More information regarding this paper and the data is given in the GitHub repository (https://github.com/sgielis/WT1_TCR) The raw folder contains all MiXCR files for the two studied WT1 epitopes and two VZV epitopes. The VZV epitopes were not taken into account in this paper, but were used to build VZV-specific TCRex models for another paper [in submission]. Since all TCRs for the 4 epitopes were sequences together, this data was used for quality control purposes as explained in the paper. Following 4 folders are present: <ul> <li>run1: TCR data from the first run for WT1-126, WT1-37 and IE62</li> <li>run1_orf18: TCR data from the first run for ORF18</li> <li>run2: WT1-37 data filtered on high and low threshold gating.</li> <li>run 3: extra TCR data for WT1-126, WT1-37 aligned with MiXCR</li> </ul>

dryad36/100

Study group charasteristics and sequencing data of patients with essential thrombocythemia and polycythemia vera

Polycythemia vera (PV) and essential thrombocythemia (ET) are diseases driven by canonical mutations in JAK2, CALR, or MPL gene. Previous studies revealed that in addition to driver mutations, patients with PV and ET can harbor other mutations in various genes, with no established impact on disease phenotype. We hypothesized that the molecular profile of patients with PV and ET is dynamic throughout the disease. In this study we performed 37-gene targeted next-generation sequencing panel on the DNA samples collected from 49 study participants in two time points, separated by 78-141 months. We identified 78 variants across 37 analyzed genes in the study population. By analyzing the change in variant allele frequencies (VAFs) and revealing the acquisition of new mutations during the disease, we confirmed the dynamic nature of molecular profile of patients with PV and ET. We found connections of specific variants with the development of secondary myelofibrosis, thrombotic events, and response to treatment. We confronted our results with existing conventional and mutation-enhanced prognostic systems, showing the limited utility of available prognostic tools. Results of this study underline the significance of repeated molecular testing in patients with PV and ET and indicate the need for further research within this field to better understand the disease and improve available prognostic tools.

opencc-zeroAug 2023View details →

opencc-by-4.0Aug 2023View details →

Single Cell RNA sequencing data of ADT treated Prostate cancer patients

The data was generated from a study that was conducted according to guidelines approved by the Review Board at the University of Texas Southwestern Medical Center. We procured patient biopsy samples from two distinct studies. The first is titled "Tissue Collection and Results Gathering for Radiotherapy Patients & Healthy Individuals" (STU 072010-098), and the second is a Phase I Clinical Study on Stereotactic Ablative Radiotherapy (SABR) for Pelvic and Prostate Areas in High-Risk Prostate Cancer Patients (STU062014-027). The single-cell RNA sequencing (scRNA-seq) took place in Dr. Douglas Strand's laboratory, adhering to the method outlined in Henry et al1. We used a 1-hour treatment with 5mg/ml of collagenase type I, 10mM of ROCK inhibitor, and 1mg of DNase. Barcode labeling for 3' GEX was done using a 10X machine, and the sequencing process utilized an Illumina NextSeq 500 device.   1. Henry, G. H., Malewska, A., Joseph, D. B., Malladi, V. S., Lee, J., Torrealba, J., ... & Strand, D. W. (2018). A cellular anatomy of the normal adult human prostate and prostatic urethra. Cell reports, 25(12), 3530-3542.

opencc-by-4.0Sep 2023View details →

Data for A Far-Red Fluorescent Probe to Visualize Staphylococcus aureus in Patient Samples

Raw and processed data supporting the manuscript "A Far-Red Fluorescent Probe to Visualize Staphylococcus aureus in Patient Samples"

controlledIPD-YESFeb 2026View details →

Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy

ClinicalTrials.gov study NCT04134429. IPD Sharing: YES. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →

Assessing the Performance of Artificial Intelligence (AI)-Augmented Electronic Health Record (EHR) Data Abstraction for Clinical Trial Patient Screening

ClinicalTrials.gov study NCT06561217. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →

Development and Validation of a Deep Learning-Based Survival Prediction Model for Pediatric Glioma Patients: A Retrospective Study Using the SEER Database and Chinese Data

ClinicalTrials.gov study NCT06199388. IPD Sharing: NO. Countries: 1. Publications: 2.

closedIPD-NOFeb 2026View details →

Development of a Dietary Intervention Model Based on Genetic Data as an Implementation of a Healthy Lifestyle in the Management of Systemic Lupus Erythematosus Patients

ClinicalTrials.gov study NCT07183007. IPD Sharing: NO. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →

Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data

ClinicalTrials.gov study NCT04606264. IPD Sharing: YES. Countries: 1. Publications: 1.